Bristol-Myers Squibb Company (BMY) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1101221083

Cancer, Blood, Arthritis, Heart, Melanoma, Multiple Sclerosis

Bristol-Myers Squibb Company is a global biopharmaceutical powerhouse that discovers, develops, and delivers life-changing medicines to patients worldwide. The company's portfolio boasts a diverse range of innovative products that cater to various therapeutic areas, including hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.

Its flagship products include Eliquis, a leading oral anticoagulant that reduces the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, as well as treats deep vein thrombosis and pulmonary embolism. Opdivo, a groundbreaking cancer treatment, has received approvals for multiple indications, including bladder, blood, colorectal, head and neck, kidney, liver, lung, melanoma, mesothelioma, stomach, and esophageal cancers.

The company's oncology franchise also features Pomalyst/Imnovid, a treatment for multiple myeloma, and Yervoy, which targets unresectable or metastatic melanoma. Additionally, Bristol-Myers Squibb offers Orencia for rheumatoid arthritis and psoriatic arthritis, as well as Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia.

Its pipeline continues to expand with innovative therapies, such as Abecma for relapsed or refractory multiple myeloma, Reblozyl for anemia, Opdualag for unresectable or metastatic melanoma, and Zeposia for relapsing forms of multiple sclerosis. The company has also introduced Breyanzi for relapsed or refractory large B-cell lymphoma, Onureg for acute myeloid leukemia, Inrebic for myelofibrosis, and Camzyos for symptomatic obstructive hypertrophic cardiomyopathy.

Bristol-Myers Squibb's commercial reach spans across the globe, with products sold to a network of wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. With a rich history dating back to 1887, the company continues to drive innovation and improve patient outcomes from its headquarters in Princeton, New Jersey.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Bristol-Myers Squibb Company (BMY) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Bristol-Myers Squibb Company (BMY) - Stock & Dividends

BMY Stock Overview

Market Cap in USD 88,523m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1972-01-01

BMY Stock Ratings

Growth 5y 0.04
Fundamental 35.9
Dividend 8.32
Rel. Performance vs Sector -5.43
Analysts 3.32/5
Fair Price Momentum 41.86 USD
Fair Price DCF 169.14 USD

BMY Dividends

Yield 12m 5.78%
Yield on Cost 5y 6.10%
Dividends CAGR 5y 6.81%
Payout Consistency 94.1%

BMY Growth Ratios

Growth 12m -33.72%
Growth Correlation 12m -68%
Growth Correlation 3m -67%
CAGR 5y 1.08%
CAGR/Mean DD 5y 0.09
Sharpe Ratio 12m -1.82
Alpha vs SP500 12m -53.24
Beta vs SP500 5y weekly 0.63
ValueRay RSI 4.16
Volatility GJR Garch 1y 25.44%
Price / SMA 50 -14.52%
Price / SMA 200 -21%
Current Volume 14673.9k
Average Volume 20d 13638.9k

External Links for BMY Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of BMY stocks?
As of May 30, 2024, the stock is trading at USD 40.49 with a total of 14,673,932 shares traded.
Over the past week, the price has changed by -4.21%, over one month by -9.30%, over three months by -19.56% and over the past year by -33.72%.
What are the forecast for BMY stock price target?
According to ValueRays Forecast Model, BMY Bristol-Myers Squibb Company will be worth about 45.3 in May 2025. The stock is currently trading at 40.49. This means that the stock has a potential upside of +11.76%.
Issuer Forecast Upside
Wallstreet Target Price 52.3 29.0
Analysts Target Price 71.6 76.8
ValueRay Target Price 45.3 11.8

The Journey of Bristol-Myers Squibb: Innovation and Growth

Bristol-Myers Squibb (BMS), a global biopharmaceutical company, has a rich history dating back to the 19th century. It was formed through the merger of two companies, Bristol-Myers and Squibb, in 1989. This merger combined Bristol-Myers' expertise in over-the-counter medications and Squibb's pioneering work in antibiotic production, setting the stage for a company committed to research, development, and the distribution of innovative medications.

Core Business: A Focus on Life-Changing Medicines

At the heart of BMS's operations is its dedication to developing life-changing medicines. The company focuses on several therapeutic areas including oncology, cardiovascular diseases, immunoscience, and fibrosis. BMS is widely recognized for its revolutionary cancer drugs and treatments for heart diseases and rheumatoid arthritis, products that have not only improved patient outcomes but have also contributed significantly to the company's growth and market presence.

Expanding Horizons: Side Businesses and Collaborations

Beyond its primary focus, BMS has ventured into related healthcare sectors through acquisitions and strategic partnerships. These moves have enabled the company to expand its product portfolio into areas such as gene therapy and cell therapy. For instance, the acquisition of Celgene in 2019 significantly bolstered BMS's position in the oncology and immunology markets, adding several blockbuster drugs to its lineup.

Current Market Status: Maintaining a Strong Presence

Today, Bristol-Myers Squibb stands as a formidable player in the global biopharmaceutical market. It enjoys a strong financial performance, with robust revenues driven by its leading drug offerings. The company's strategy of focusing on high-growth areas in medicine, along with a continued commitment to research and development, positions it well for future growth. However, like all companies in the pharmaceutical industry, BMS faces challenges such as patent expirations, regulatory hurdles, and intense competition.

In conclusion, Bristol-Myers Squibb's journey from its 19th-century origins to a 21st-century biopharmaceutical leader is a testament to its innovative spirit, strategic growth initiatives, and unwavering commitment to improving patient health. As it looks to the future, BMS's blend of cutting-edge research, strategic collaborations, and a diverse product portfolio will likely continue to be key drivers of its success.